297 related articles for article (PubMed ID: 20146718)
1. Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation.
Kong YC; Wei WZ; Tomer Y
Ann N Y Acad Sci; 2010 Jan; 1183():222-36. PubMed ID: 20146718
[TBL] [Abstract][Full Text] [Related]
2. Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1.
Kong YC; Flynn JC
Front Immunol; 2014; 5():206. PubMed ID: 24904570
[TBL] [Abstract][Full Text] [Related]
3. Is autoimmunity the Achilles' heel of cancer immunotherapy?
June CH; Warshauer JT; Bluestone JA
Nat Med; 2017 May; 23(5):540-547. PubMed ID: 28475571
[TBL] [Abstract][Full Text] [Related]
4. Treatment of refractory autoimmune diseases with ablative immunotherapy using monoclonal antibodies and/or high dose chemotherapy with hematopoietic stem cell support.
Cohen Y; Polliack A; Nagler A
Curr Pharm Des; 2003; 9(3):279-88. PubMed ID: 12570832
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune Cardiotoxicity of Cancer Immunotherapy.
Cheng F; Loscalzo J
Trends Immunol; 2017 Feb; 38(2):77-78. PubMed ID: 27919707
[TBL] [Abstract][Full Text] [Related]
6. Interferon alpha and its contribution to autoimmunity.
Selmi C; Lleo A; Zuin M; Podda M; Rossaro L; Gershwin ME
Curr Opin Investig Drugs; 2006 May; 7(5):451-6. PubMed ID: 16729722
[TBL] [Abstract][Full Text] [Related]
7. Progress toward production of immunologic tolerance with no or minimal toxic immunosuppression for prevention of immunodeficiency and autoimmune diseases.
Good RA
World J Surg; 2000 Jul; 24(7):797-810. PubMed ID: 10833246
[TBL] [Abstract][Full Text] [Related]
8. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
9. Opportunistic infections and other risks with newer multiple sclerosis therapies.
Berger JR; Houff S
Ann Neurol; 2009 Apr; 65(4):367-77. PubMed ID: 19399841
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies.
Ferrari SM; Fallahi P; Elia G; Ragusa F; Ruffilli I; Patrizio A; Galdiero MR; Baldini E; Ulisse S; Marone G; Antonelli A
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137683
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy in patients with preexisting autoimmune disorders.
Donia M; Pedersen M; Svane IM
Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287
[TBL] [Abstract][Full Text] [Related]
12. What did we learn from CTLA-4 insufficiency on the human immune system?
Mitsuiki N; Schwab C; Grimbacher B
Immunol Rev; 2019 Jan; 287(1):33-49. PubMed ID: 30565239
[TBL] [Abstract][Full Text] [Related]
13. To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease.
Pantuck M; McDermott D; Drakaki A
Cancer; 2019 Oct; 125(20):3506-3513. PubMed ID: 31318445
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States.
Sullivan KM; Muraro P; Tyndall A
Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S48-56. PubMed ID: 19895895
[TBL] [Abstract][Full Text] [Related]
16. Management of autoimmune diseases after haematopoietic stem cell transplantation.
Holbro A; Abinun M; Daikeler T
Br J Haematol; 2012 May; 157(3):281-90. PubMed ID: 22360687
[TBL] [Abstract][Full Text] [Related]
17. Stem cell transplantation for autoimmune diseases.
Burt RK; Verda L; Statkute L; Quigley K; Yaung K; Brush M; Oyama Y
Clin Adv Hematol Oncol; 2004 May; 2(5):313-9. PubMed ID: 16163198
[TBL] [Abstract][Full Text] [Related]
18. Autoimmunity following haematopoietic stem-cell transplantation.
Daikeler T; Tyndall A
Best Pract Res Clin Haematol; 2007 Jun; 20(2):349-60. PubMed ID: 17448966
[TBL] [Abstract][Full Text] [Related]
19. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge.
Kostine M; Chiche L; Lazaro E; Halfon P; Charpin C; Arniaud D; Retornaz F; Blanco P; Jourde-Chiche N; Richez C; Stavris C
Rev Med Interne; 2017 Aug; 38(8):513-525. PubMed ID: 28214182
[TBL] [Abstract][Full Text] [Related]
20. Treatment of refractory autoimmune diseases with ablative immunotherapy.
Cohen Y; Nagler A
Autoimmun Rev; 2004 Feb; 3(2):21-9. PubMed ID: 15003184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
